$HQY

Fiore Michael Henry sold $224K of HQY

Fiore Michael Henry (EVP, CHIEF COMMERCIAL OFFICER) sold 2,354 shares of HEALTHEQUITY, INC. (HQY) at $95.00 ($0.22M total) on 2026-07-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fiore Michael Henry
Published Jul 14, 2026, 8:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HQY
Neutral
high confidence
Mentioned
$HQY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HQYNeutralLow
01

Why it matters

The disclosed sale is planned under a Rule 10b5-1 arrangement, which typically reduces interpretive weight versus discretionary sales.

02

Market read

Traders may note the confirmed insider selling activity, but there is no new fundamental catalyst in the text.

03

What to watch

The article does not state whether other insiders sold/bought, whether the plan size is typical, or whether there were concurrent corporate events that could contextualize the sale.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-14, covering a sale executed 2026-07-10.

Background

The article is an SEC Form 4 insider transaction disclosure for HEALTHEQUITY, INC. (HQY).

Company-level read

Ticker impact

$HQYNeutralHigh confidence
Context

SEC Form 4 shows HQY officer Fiore Michael Henry sold 2,354 shares on 2026-07-10 at $95.00/share under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a disclosed open-market sale by an EVP under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or operational change.

Market effects

No clear sector read-through; this is company-specific insider liquidity disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can still coincide with private views on near-term risk, even when executed under a 10b5-1 plan.

Key entities

  • HEALTHEQUITY, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Fiore Michael Henry

    EVP, Chief Commercial Officer who sold shares.

Related articles

$HQYMed

HealthEquity rating upgraded by Moody’s on strong cash flow

Moody’s upgraded HealthEquity, Inc. (NASDAQ:HQY) corporate family rating to Ba2 from Ba3 and raised its probability of default rating to Ba2-PD from Ba3-PD. It also upgraded $600 million senior unsecured notes to Ba3 from B1, with outlook changed to stable. Moody’s cited stronger operating cash flow and BenefitWallet integration, plus improved leverage and liquidity.

$HQYMedAI 9/10

HealthEquity Q1 2027 Earnings Call: Complete Transcript - HealthEquity (NASDAQ: HQY)

HealthEquity reported fiscal 2027 first-quarter results, citing 7% year-over-year revenue growth and a record adjusted EBITDA margin of 46%, according to the company. It raised guidance to $1.41–$1.42B revenue and $625–$633M adjusted EBITDA. The firm said it expanded digital engagement and Marketplace, used AI for efficiency, saw HSA assets +19% and new HSA sales +15%, and increased its share repurchase authorization by $1B.